Acer Therapeutics Future Growth

Future criteria checks 5/6

Acer Therapeutics is forecast to grow earnings and revenue by 66.2% and 50.8% per annum respectively while EPS is expected to grow by 70.9% per annum.

Key information

66.2%

Earnings growth rate

70.9%

EPS growth rate

Pharmaceuticals earnings growth	22.8%
Revenue growth rate	50.8%
Future return on equity	n/a
Analyst coverage	Low
Last updated	05 Sep 2023

Recent future growth updates

Recent updates

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

Oct 05

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

Aug 12

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Jul 28

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Feb 25

Acer Therapeutics completes enrollment in ACER-001 bioequivalence trial for urea cycle disorders

Dec 22

Earnings and Revenue Growth Forecasts

OTCPK:ACER - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	110	28	N/A	N/A	1
12/31/2024	48	4	N/A	N/A	2
12/31/2023	9	-22	N/A	N/A	2
6/30/2023	N/A	-39	-32	-32	N/A
3/31/2023	N/A	-33	-36	-36	N/A
12/31/2022	N/A	-26	-30	-30	N/A
9/30/2022	0	-21	-23	-23	N/A
6/30/2022	0	-20	-22	-22	N/A
3/31/2022	0	-20	-6	-6	N/A
12/31/2021	1	-15	0	0	N/A
9/30/2021	1	-17	-3	-3	N/A
6/30/2021	1	-20	1	1	N/A
3/31/2021	1	-23	-9	-9	N/A
12/31/2020	N/A	-23	-17	-17	N/A
9/30/2020	N/A	-22	-17	-17	N/A
6/30/2020	N/A	-21	-20	-20	N/A
3/31/2020	N/A	-26	-25	-25	N/A
12/31/2019	N/A	-29	-30	-30	N/A
9/30/2019	N/A	-33	-30	-30	N/A
6/30/2019	N/A	-31	-28	-27	N/A
3/31/2019	N/A	-25	-23	-23	N/A
12/31/2018	N/A	-21	-17	-17	N/A
9/30/2018	N/A	-17	-16	-16	N/A
6/30/2018	N/A	-17	-17	-17	N/A
3/31/2018	N/A	-15	-15	-15	N/A
12/31/2017	N/A	-14	-14	-14	N/A
9/30/2017	N/A	-12	-12	-12	N/A
6/30/2017	N/A	-11	-9	-9	N/A
3/31/2017	N/A	-9	N/A	-9	N/A
12/31/2016	N/A	-7	N/A	-7	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACER is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: ACER is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ACER is expected to become profitable in the next 3 years.

Revenue vs Market: ACER's revenue (50.8% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: ACER's revenue (50.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ACER's Return on Equity is forecast to be high in 3 years time

Acer Therapeutics Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus forecasts updated

Consensus revenue estimates fall by 29%

No longer forecast to breakeven

Consensus forecasts updated

Consensus revenue estimates increase to US$8.00m

Recent updates

Acer Therapeutics Inc. Files Form 15

Acer Therapeutics Inc. Announces Executive Changes

Nasdaq to Delist the Securities of Acer Therapeutics

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc.(OTCPK:ACER) dropped from S&P TMI Index

Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) entered into definitive Agreement to acquire Acer Therapeutics Inc. (NasdaqCM:ACER) for $91 million.

Acer Therapeutics Receives a Letter from Nasdaq Indicating the Company Is Not in Compliance with the $1.00 Minimum Bid Price Requirement Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Acer Therapeutics Inc. Receives Non-Compliance Notice From Nasdaq

Acer Therapeutics Announces Full Enrollment of Phase 2A Trial of Acer-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Acer Therapeutics Inc. Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate

Acer Therapeutics Compliant with All Nasdaq Listing Criteria

Acer Therapeutics Inc. announced that it has received $1.5 million in funding

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.23 loss in 3Q 2021)

Insufficient new directors

Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)

Acer Therapeutics Inc. Announces Receipt of Notice of Allowance of US Patent Application Covering Kit Comprising Phenylbutyrate and Sodium Benzoate

Acer Therapeutics Inc. Announces Expansion of Acer-801 (Osanetant) Development Indications to Include Post-Traumatic Stress Disorder

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

First half 2022 earnings released: US$0.80 loss per share (vs US$0.54 loss in 1H 2021)

RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Commission Has Granted Orphan Drug Designation for Acer-001 in Maple Syrup Urine Disease

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Acer resubmits U.S. marketing application for urea cycle disorder therapy

Acer Therapeutics Inc. Resubmittes the ACER-001 New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders

Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome

Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application for ACER-001

Acer Therapeutics Not Yet Received Decision from the U.S. Food and Drug Administration on ACER-001

Acer Therapeutics Receives a Letter from the Listing Qualifications Department Staff of the Nasdaq Stock Market Regarding Minimum Market Value of Listed Securities

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Acer Therapeutics Inc. Provides an Update on the Recent Corporate Developments

Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients

Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer-001 Data At the Genetic Metabolic Dieticians International Conference

Insufficient new directors

Acer Therapeutics Inc., Annual General Meeting, May 20, 2022

Acer Therapeutics Inc. and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

Acer Therapeutics’ EDSIVO Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome

Acer Therapeutics Regains Compliance with Nasdaq Listing Standard

Acer Therapeutics Enrolls First Patient in Its Phase 2A Clinical Trial of Acer-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Consensus revenue estimates fall by 29%

Acer Therapeutics Inc. Announces Appointment of Adrian Quartel as Chief Medical Officer

Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth

No longer forecast to breakeven

Acer Therapeutics Inc. Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms

Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases

Consensus forecasts updated

Acer Therapeutics Plans Clinical Trial for Edsivo Following Type B FDA Meeting

Acer Expands Its Predator Gaming Portfolio with Three New HDR Monitors

Acer Therapeutics Plans NDA Submission for Acer-001 in Third Quarter 2021 Following Pre-NDA Meeting with FDA

Consensus revenue estimates increase to US$8.00m

We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate

Acer Therapeutics Inc. Announces Update on Settlement of Derivative Suits

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Acer Therapeutics Inc. Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions

Relief Therapeutics and Acer Therapeutics Sign Option Agreement to Pursue a Potential Collaboration and License Arrangement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

New 90-day high: US$3.85

Acer Therapeutics completes enrollment in ACER-001 bioequivalence trial for urea cycle disorders

Acer Therapeutics Inc. Announces Publication of Additional Long-Term Data from COL3A1-Positive Vascular Ehlers-Danlos Syndrome (vEDS) Patients

New 90-day low - US$2.44

New 90-day high - US$5.41

Acer Therapeutics Inc. announced that it expects to receive $0.857493 million in funding

Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell 2000 Dynamic Index

Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell Small Cap Completeness Index

Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell Microcap Index

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity